二甲双胍对伴有 2 型糖尿病的局部进展期胃癌患者预后的影响。
The Effect of Metformin on Prognosis in Patients With Locally Advanced Gastric Cancer Associated With Type 2 Diabetes Mellitus.
机构信息
Department of Surgery, Division of Gastrointestinal Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
出版信息
Am J Clin Oncol. 2019 Dec;42(12):909-917. doi: 10.1097/COC.0000000000000627.
OBJECTIVES
This study examined the effect of metformin use on the prognosis of gastric cancer patients.
MATERIALS AND METHODS
The study population comprised 2187 patients who underwent curative gastrectomy for the treatment of gastric cancer. They were divided into 3 groups: metformin (n=103), non-metformin (n=139), and non-diabetes mellitus (DM) (n=1945) according to their history of type 2 DM and metformin use. Survival, disease recurrence, and the pathologic stage were analyzed.
RESULTS
Overall survival was better in the metformin group than in the non-DM group (P=0.005). Metformin use was an independent prognostic factor of overall survival, cancer recurrence, and peritoneal recurrence. An effect of metformin use was especially notable in patients with T4 or N0 disease.
CONCLUSIONS
Metformin improves the survival of patients with gastric cancer and type 2 DM.
目的
本研究旨在探讨二甲双胍对胃癌患者预后的影响。
材料与方法
本研究纳入了 2187 例接受根治性胃切除术治疗胃癌的患者。根据患者的 2 型糖尿病病史和二甲双胍使用情况，将其分为 3 组：二甲双胍组（n=103）、非二甲双胍组（n=139）和非糖尿病组（n=1945）。分析生存情况、疾病复发情况和病理分期。
结果
与非糖尿病组相比，二甲双胍组的总生存率更好（P=0.005）。二甲双胍的使用是总生存率、癌症复发和腹膜复发的独立预后因素。二甲双胍的使用效果在 T4 或 N0 疾病患者中尤为显著。
结论
二甲双胍可改善胃癌合并 2 型糖尿病患者的生存。
Zotero 插件